|
|
|
VII POPULATION STUDIES: VITAMIN D DEFICIENCY, NUTRITION, SUNLIGHT, GENES & TRIALS |
|
|
|
58 Methods of Evaluating Population Studies of Vitamin D: Strengths and Weaknesses |
|
|
|
|
|
3 | (1) |
|
Methods of Assessing Vitamin D Status |
|
|
4 | (3) |
|
Main Challenges in the Epidemiologic Study of Vitamin D and Disease |
|
|
7 | (2) |
|
Summary of Study Designs of Vitamin D |
|
|
9 | (3) |
|
|
12 | (1) |
|
|
13 | (2) |
|
59 Worldwide Vitamin D Status |
|
|
|
|
|
|
15 | (1) |
|
Vitamin D Status in North America (Including Canada and Mexico) |
|
|
16 | (5) |
|
Vitamin D Status in South America |
|
|
21 | (1) |
|
Vitamin D Status in Europe |
|
|
21 | (1) |
|
Vitamin D Status in Middle East |
|
|
21 | (1) |
|
|
21 | (1) |
|
Vitamin D Status in Africa |
|
|
21 | (5) |
|
Vitamin D Status in Oceania |
|
|
26 | (1) |
|
Multicenter and Global Studies Using a Central Laboratory Facility |
|
|
26 | (8) |
|
|
34 | (1) |
|
|
34 | (1) |
|
|
34 | (1) |
|
|
34 | (1) |
|
|
35 | (1) |
|
|
35 | (6) |
|
60 Vitamin D in Foods: An Evolution of Knowledge |
|
|
|
|
|
|
|
|
|
41 | (1) |
|
Challenges in Assessing the Vitamin D Content of Foods |
|
|
42 | (5) |
|
Methods of Analysis for Vitamin D in Foods |
|
|
47 | (7) |
|
|
54 | (7) |
|
Implications and Future Directions |
|
|
61 | (1) |
|
|
62 | (12) |
|
|
74 | (5) |
|
61 Determinants of Vitamin D Deficiency From Sun Exposure: A Global Perspective |
|
|
|
|
|
|
|
79 | (1) |
|
Factors Affecting 25-Hydroxyvitamin D Concentrations |
|
|
80 | (6) |
|
Predicting Vitamin D Deficiency |
|
|
86 | (1) |
|
|
86 | (1) |
|
|
86 | (5) |
|
62 Vitamin D Fortification and Supplementation Policies to Correct Vitamin D Insufficiency/Deficiency Globally |
|
|
|
|
|
|
91 | (3) |
|
Recommendations for Vitamin D Status |
|
|
94 | (5) |
|
Strategies to Improve Nutrient Intakes |
|
|
99 | (5) |
|
Public Health Measures for Reducing D Deficiency |
|
|
104 | (2) |
|
|
106 | (1) |
|
|
106 | (3) |
|
63 Vitamin D and Food Fortification |
|
|
|
|
|
|
109 | (3) |
|
Current Intakes of Vitamin D in Young and Adult Populations in North America and Europe and How These Compare Against Dietary Targets? |
|
|
112 | (1) |
|
Dietary Strategies for Increasing Vitamin D Intake: Bridging the Gap By Food Fortification |
|
|
112 | (8) |
|
Consideration of Other Vitamin D-Fortified Foods |
|
|
120 | (1) |
|
Vitamin D-Biofortified Foods |
|
|
121 | (2) |
|
Safety Considerations and Prerequisite Data Required Prior to Initiating Public Health Measures |
|
|
123 | (1) |
|
|
124 | (1) |
|
|
125 | (4) |
|
64 Bariatric Surgery, Vitamin D, and Bone Loss |
|
|
|
|
|
|
129 | (2) |
|
Skeletal Effects of Bariatric Surgery |
|
|
131 | (3) |
|
Potential Mechanisms of Bone Loss |
|
|
134 | (9) |
|
Prevention and Treatment of Skeletal Effects |
|
|
143 | (2) |
|
|
145 | (1) |
|
|
145 | (6) |
|
65 Genetics of the Vitamin D Endocrine System |
|
|
|
|
|
151 | (2) |
|
|
153 | (4) |
|
Genome-Wide Association Studies |
|
|
157 | (5) |
|
|
162 | (1) |
|
|
162 | (1) |
|
|
162 | (5) |
|
66 Randomized Clinical Trials of Vitamin D for the Primary Prevention of Cancer and Cardiovascular Disease With a Focus on the VITamin D and OmegA-3 Trial (VITAL) |
|
|
|
|
|
|
167 | (1) |
|
Vitamin D and Omega-3 Trial Study Design |
|
|
168 | (2) |
|
Baseline Characteristics of VITAL Participants |
|
|
170 | (3) |
|
Other Ongoing and Recently Completed Large and Midsized Trials of Vitamin D |
|
|
173 | (1) |
|
|
174 | (1) |
|
|
174 | (1) |
|
|
175 | (4) |
|
|
|
67 Vitamin D Deficiency and Nutritional Rickets in Children |
|
|
|
|
|
|
|
179 | (1) |
|
|
179 | (1) |
|
The Epidemiology of Vitamin D Deficiency and Nutritional Rickets |
|
|
180 | (2) |
|
|
182 | (2) |
|
Biochemical Abnormalities |
|
|
184 | (1) |
|
|
185 | (1) |
|
The Growth Plate in Rickets |
|
|
186 | (1) |
|
|
187 | (3) |
|
Dietary Calcium Deficiency |
|
|
190 | (2) |
|
The Pathogenetic Spectrum of Nutritional Rickets |
|
|
192 | (1) |
|
|
193 | (1) |
|
|
194 | (10) |
|
68 Vitamin D and Osteoporosis |
|
|
|
|
|
Effects of Vitamin D on the Skeleton |
|
|
204 | (1) |
|
The Role of Vitamin D Genetic Factors in Osteoporosis and Possible Interactions With Vitamin D Therapy |
|
|
205 | (2) |
|
Determining Optimal Serum 25 Hydroxyvitamin D Concentrations for Musculoskeletal Health |
|
|
207 | (1) |
|
Effects of Vitamin D Alone or Calcium and Vitamin D on Bone Mineral Density |
|
|
207 | (2) |
|
Primary Fracture Prevention With Vitamin D or Calcium and Vitamin D |
|
|
209 | (1) |
|
Effect of Vitamin D Alone on Fractures |
|
|
209 | (1) |
|
Single High Annual or Monthly Doses of Vitamin D |
|
|
210 | (1) |
|
Primary Fracture Prevention With Calcium and Vitamin D |
|
|
211 | (1) |
|
|
212 | (1) |
|
|
213 | (1) |
|
Secondary Fracture Prevention With Vitamin D or Calcium and Vitamin D |
|
|
214 | (1) |
|
Effects of Active Vitamin D Analogs on Fractures |
|
|
215 | (1) |
|
The Anabolic Vitamin D Analogs, 2MD |
|
|
215 | (1) |
|
The Vitamin D Analogs, Eldecalcitol |
|
|
215 | (1) |
|
Ongoing Large Randomized Controlled Trials of Vitamin D Supplementation |
|
|
216 | (1) |
|
Future Directions for Vitamin D in Osteoporosis |
|
|
216 | (1) |
|
|
216 | (5) |
|
69 Adult Vitamin D Deficiency: Fracture and Fall Prevention |
|
|
|
|
Heike A. Bischoff-Ferrari |
|
|
Vitamin D: Muscle and Balance |
|
|
221 | (1) |
|
|
222 | (2) |
|
Vitamin D: Bone Mineral Density and Fracture Risk |
|
|
224 | (1) |
|
Trials Testing Higher Doses of Vitamin D Given at Infrequent Intervals |
|
|
225 | (1) |
|
|
226 | (1) |
|
|
226 | (3) |
|
70 Clinical Disorders of Phosphate Homeostasis |
|
|
|
|
|
|
229 | (1) |
|
Regulation of Phosphate Homeostasis |
|
|
230 | (1) |
|
Phosphate and Vitamin D Metabolism |
|
|
231 | (1) |
|
Clinical Symptoms of Hypophosphatemia and Hyperphosphatemia |
|
|
231 | (1) |
|
Disorders of Phosphate Homeostasis |
|
|
232 | |
|
Genetic Hypophosphatemic Disorders With Low Fibroblast Growth Factor |
|
|
23 | (216) |
|
|
239 | |
|
Acquired Hypophosphatemic Disorders With Elevated Fibroblast Growth Factor |
|
|
23 | (216) |
|
|
239 | (1) |
|
Genetic Hyperphosphosphatemic Disorders |
|
|
240 | (1) |
|
Disorders of Altered Phosphate Load |
|
|
240 | (1) |
|
|
241 | (8) |
|
71 Vitamin D Hydroxylation--Deficient Rickets, Type 1A: CYP27B1 Mutations |
|
|
|
|
|
|
249 | (1) |
|
|
250 | (1) |
|
|
251 | (1) |
|
Genetic and Molecular Studies |
|
|
252 | (3) |
|
|
255 | (1) |
|
Evolution of VDDR1A Under Treatment From Childhood to Adulthood |
|
|
255 | (3) |
|
Perspective and Conclusions |
|
|
258 | (2) |
|
|
260 | (4) |
|
72 Hereditary 1,25-Dihydroxyvitamin D Resistant Rickets |
|
|
|
|
|
|
|
264 | (1) |
|
The Clinical Features of HVDRR |
|
|
264 | (6) |
|
Mechanism of 1,25(OH)2D Action |
|
|
270 | (2) |
|
|
272 | (6) |
|
Molecular Basis for HVDRR |
|
|
278 | (11) |
|
|
289 | (3) |
|
|
292 | (1) |
|
|
293 | (1) |
|
|
294 | (9) |
|
73 The Role of Genetic Variation in CYP2R1, the Principal Vitamin D 25-Hydroxylase, in Vitamin D Homeostasis |
|
|
|
|
|
|
303 | (1) |
|
CYP2R1 Is the Principal Human Vitamin D 25-Hydroxylase |
|
|
304 | (3) |
|
CYP2R1 and Vitamin D-Dependent Rickets |
|
|
307 | (3) |
|
In Vitro and In Silico Analyses of CYP2R1 Function |
|
|
310 | (2) |
|
Associations Between CYP2R1 Variants and Disease |
|
|
312 | (1) |
|
Conclusion and Future Directions |
|
|
313 | (1) |
|
|
313 | (4) |
|
74 Infantile Hypercalcemia and CYP24A1 Mutations |
|
|
|
|
|
Infantile Hypercalcemia---Differential Diagnosis |
|
|
317 | (2) |
|
Idiopathic Infantile Hypercalcemia---Historical Aspects |
|
|
319 | (1) |
|
Spectrum of Disease Caused By CYP24A1 Mutations |
|
|
320 | (3) |
|
Mutations In CVP24A1---Molecular Genetics |
|
|
323 | (1) |
|
Functional Studies of Mutant CYP24A1 |
|
|
324 | (1) |
|
Measurement of CYP24A1 Activity In Vivo |
|
|
324 | (1) |
|
|
325 | (1) |
|
Additional Defects Leading to an Increased Action of Vitamin D |
|
|
325 | (1) |
|
|
326 | (1) |
|
|
327 | (1) |
|
|
328 | (3) |
|
75 Drug and Hormone Effects on Vitamin D Metabolism |
|
|
|
|
|
|
331 | (2) |
|
Hormone Effects on Vitamin D Metabolism |
|
|
333 | (9) |
|
Drug Effects on Vitamin D Metabolism |
|
|
342 | (12) |
|
|
354 | (1) |
|
|
354 | (21) |
|
76 Vitamin D and Organ Transplantation |
|
|
|
|
|
|
|
|
375 | (1) |
|
Effects of Vitamin D on Immunity and Graft Rejection |
|
|
375 | (1) |
|
Vitamin D Deficiency Prior to Organ Transplant |
|
|
376 | (1) |
|
Vitamin D Deficiency Following Organ Transplant |
|
|
377 | (1) |
|
Treatment of Posttransplant Bone Loss With Vitamin D and Analogs |
|
|
378 | (3) |
|
|
381 | (1) |
|
|
381 | |
|
|
373 | (15) |
|
77 The Role of Vitamin D in Type 2 Diabetes and Hypertension |
|
|
|
|
|
Epidemiology and Burden of Type 2 Diabetes and Hypertension |
|
|
388 | (1) |
|
Biologic Plausibility of an Association Between Vitamin D and Type 2 Diabetes and Hypertension |
|
|
388 | (3) |
|
Evidence From Human Studies for a Link Between Vitamin D and Type 2 Diabetes |
|
|
391 | (15) |
|
Evidence From Human Studies for a Link Between Vitamin D and Hypertension |
|
|
406 | (4) |
|
Summary of Evidence From Human Studies on Type 2 Diabetes and Hypertension and Limitations in the Study of Vitamin D |
|
|
410 | (4) |
|
Optimal Intake of Vitamin D in Relation to Type 2 Diabetes and Hypertension |
|
|
414 | (1) |
|
|
415 | (1) |
|
|
415 | (10) |
|
78 Vitamin D, Obesity, and the Metabolic Syndrome |
|
|
|
|
|
|
425 | (1) |
|
Adipose Tissue as a Vitamin D Reserve |
|
|
426 | (1) |
|
Obesity and Vitamin D Deficiency |
|
|
426 | (2) |
|
Obesity, Vitamin D-Binding Proteins, and "Free" Vitamin D Concentrations |
|
|
428 | (1) |
|
The Effect of Weight Loss on Serum 25(OH)D Concentrations |
|
|
429 | (1) |
|
Can Vitamin D Supplementation Prevent, or Reduce, Obesity? |
|
|
430 | (1) |
|
Obesity and the Efficacy of Vitamin D Supplementation |
|
|
431 | (2) |
|
Brown Adipose Tissue, Obesity, and Vitamin D |
|
|
433 | (1) |
|
Obesity, Vitamin D, and Metabolic Syndrome |
|
|
433 | (4) |
|
Importance of Early Life D Status for Obesity and Subsequent Risks of Metabolic Syndrome, Type 2 Diabetes Mellitus, and Cardiovascular Disease |
|
|
437 | (2) |
|
Conclusions and Future Directions |
|
|
439 | (1) |
|
|
439 | (6) |
|
79 Vitamin D and Renal Disease |
|
|
|
|
|
|
445 | (3) |
|
Renal Maintenance of the Vitamin D Endocrine System |
|
|
448 | (8) |
|
Critical Calcitriol/VDR Actions to Improve Parathyroid, Skeletal, Renal, and Cardiovascular Outcomes in CKD |
|
|
456 | (7) |
|
|
463 | (1) |
|
|
463 | (8) |
|
80 Calcitriol and Analogs in the Treatment of Chronic Kidney Disease |
|
|
|
|
|
|
471 | (1) |
|
Analogs of Vitamin D Used in Chronic Kidney Disease |
|
|
472 | (1) |
|
Analogs in Animal Models of Uremia |
|
|
472 | (3) |
|
Chronic Kidney Disease Stages 3--4 |
|
|
475 | (2) |
|
|
477 | (3) |
|
Cardiovascular Disease in Chronic Kidney Disease and Different Forms of Vitamin D |
|
|
480 | (1) |
|
|
480 | (1) |
|
|
481 | (4) |
|
81 Idiopathic Hypercalciuria and Nephrolithiasis |
|
|
|
|
|
|
Introduction to Kidney Stones |
|
|
485 | (2) |
|
Idiopathic Hypercalciuria |
|
|
487 | (11) |
|
Current View of Human Genetic Hypercalciuria |
|
|
498 | (1) |
|
Therapeutics of Idiopathic Hypercalciuria and Effects on Calcium Metabolism |
|
|
498 | (2) |
|
Genetic Hypercalciuric Rats |
|
|
500 | (2) |
|
Risk of Stone Formation Using Vitamin D Analogs |
|
|
502 | (1) |
|
|
502 | (3) |
|
|
505 | (2) |
|
82 Hypercalcemia Due to Vitamin D Toxicity |
|
|
|
|
|
|
|
507 | (1) |
|
Forms of Exogenous Vitamin D Toxicity |
|
|
508 | (3) |
|
Forms of Endogenous Vitamin D Toxicity |
|
|
511 | (6) |
|
|
517 | (2) |
|
|
519 | (1) |
|
|
520 | (7) |
|
83 The Hypocalcemic Disorders |
|
|
|
|
|
|
|
527 | (3) |
|
Clinical Manifestations of Hypocalcemia |
|
|
530 | (1) |
|
Differential Diagnosis of Hypocalcemia |
|
|
530 | (8) |
|
Treatment of Hypocalcemia |
|
|
538 | (3) |
|
|
541 | (1) |
|
|
541 | (1) |
|
|
541 | (8) |
|
84 Vitamin D: Cardiovascular Effects and Vascular Calcification |
|
|
|
|
|
|
549 | (1) |
|
Vitamin D Signaling in Myocardial Remodeling and Function |
|
|
550 | (2) |
|
Vitamin D Actions in Atherosclerosis and Arteriosclerosis |
|
|
552 | (2) |
|
Vitamin D and Human Cardiovascular Disease: Compelling Epidemiology and Physiology, Emerging but Less Compelling Evidence of Interventional Benefit Still Persists |
|
|
554 | (1) |
|
Vitamin D Intoxication and Cardiovascular Calcification: Pharmacological Considerations |
|
|
555 | (1) |
|
The Impact of Calcium, Phosphate, and Vitamin D Excesses on Smooth Muscle Matrix Vesicle Physiology and Vascular -- Calcification |
|
|
556 | (2) |
|
The FGF23/Klotho/Vitamin D Axis, Nephrocalcinosis, and Cardiovascular Calcification |
|
|
558 | (2) |
|
Vitamin D, Vascular Parathyroid Hormone Receptor Signaling, and Arteriosclerotic Calcium Accrual: Lessons Learned From Preclinical Models and Patients With End-Stage Renal Disease |
|
|
560 | (1) |
|
Defining Cardiovascular Toxicity Thresholds for Vitamin D: Critical Clues From the Clinical Literature |
|
|
561 | (1) |
|
Vitamin D, the Calcium-Sensing Receptor, and Cardiovascular Disease |
|
|
561 | (1) |
|
Summary, Conclusions, and Future Directions |
|
|
562 | (1) |
|
|
563 | (1) |
|
|
563 | (8) |
|
85 Vitamin D and Paget's Disease |
|
|
|
|
|
|
571 | (1) |
|
Mechanism of Action of 1,25(OH)2D3 on Osteoclast Formation |
|
|
572 | (1) |
|
Increased Levels of TAF12 in Osteoclast Precursors From Paget's Disease Patients Contribute to Their Hyperresponsivity to 1,25(OH)2D3 |
|
|
572 | (1) |
|
TAF12 Expression Is Increased in Osteoclasts From Patients With Paget's Disease |
|
|
573 | (1) |
|
Overexpression of TAF12 Is Sufficient to Induce 1,25(OH)2D3 Hyperresponsivity in Human Osteoclast Precursors |
|
|
574 | (2) |
|
Mechanism of Action of TAF12 in the Increased 1,25(OH)2D3 Responsivity of OCL Precursors From PD Patients |
|
|
576 | (1) |
|
Marrow Stromal Cells Derived From p62P394L Knock-In mice and p62P392L Paget's Patients Are Hyperresponsive to 1,25(OH)2D3 and Display Enhanced RANKL Production in Response to 1,25(OH)2D3 |
|
|
576 | (1) |
|
Serum Concentrations of 1,25(OH)2D3 in Paget's Patients |
|
|
577 | (1) |
|
|
577 | (1) |
|
|
578 | (5) |
|
|
|
|
|
|
|
|
|
|
583 | (1) |
|
14-Epi Analogs of 1,25(OH)2D3 |
|
|
584 | (3) |
|
|
587 | (1) |
|
|
588 | (12) |
|
|
600 | (1) |
|
|
601 | (1) |
|
|
601 | (1) |
|
Nonsecosteroidal Compounds |
|
|
601 | (8) |
|
|
609 | (2) |
|
|
611 | (1) |
|
|
611 | (4) |
|
87 Nonsecosteroidal Ligands and Modulators of Vitamin D Receptor |
|
|
|
|
|
|
|
615 | (1) |
|
CD-Ring-Replacement Ligands |
|
|
616 | (2) |
|
|
618 | (3) |
|
Miscellaneous Nonsecosteroids |
|
|
621 | (2) |
|
Nonsecosteroidal Modulators of Vitamin D Receptor-Coregulator Interactions |
|
|
623 | (2) |
|
|
625 | (1) |
|
|
625 | (4) |
|
88 Bile Acid-Derived Vitamin D Receptor Ligands |
|
|
|
|
|
The Vitamin D Receptor Is a Dual-Functional Receptor for Vitamin D and Bile Acids |
|
|
629 | (2) |
|
Bile Acids and Nuclear Receptors |
|
|
631 | (4) |
|
Development of Bile Acid Derivatives |
|
|
635 | (2) |
|
X-Ray Crystal Structures of Vitamin D Receptor in Complex With Lithocholic Acid and Its Derivatives |
|
|
637 | (4) |
|
|
641 | (1) |
|
|
641 | (6) |
|
89 Bifunctional Vitamin D Hybrid Molecules |
|
|
|
|
|
|
647 | (1) |
|
Combination Therapy and Bifunctional Agents |
|
|
648 | (1) |
|
Nuclear Receptor Ligands as Trojan Horses |
|
|
649 | (1) |
|
Vitamin D/Histone Deacetylase Inhibitor Hybrids |
|
|
649 | (3) |
|
|
652 | (1) |
|
|
652 | (1) |
|
|
653 | (1) |
|
|
653 | (4) |
|
90 Modulating Vitamin D Receptor-Coregulator Binding With Small Molecules |
|
|
|
|
|
|
657 | (1) |
|
Vitamin D Receptor Coactivators |
|
|
657 | (1) |
|
Vitamin D Receptor Corepressors |
|
|
658 | (1) |
|
Inhibiting Vitamin D Receptor: VDR Antagonists Versus VDR--Coregulator Inhibitors |
|
|
659 | (2) |
|
Peptide-Based Inhibitors of Vitamin D Receptor-Coregulator Interactions |
|
|
661 | (2) |
|
Small Molecule-Based Inhibitors of Vitamin D Receptor-Coregulator Interactions |
|
|
663 | (1) |
|
Conclusion and Future Direction |
|
|
664 | (1) |
|
|
664 | (1) |
|
|
664 | (3) |
|
91 Extended-Release Calcifediol in Renal Disease |
|
|
|
|
|
|
667 | (1) |
|
Background---Vitamin D Signaling and Metabolism |
|
|
668 | (2) |
|
Treating Secondary Hyperparathyroidism Associated With Vitamin D Insufficiency in Chronic Kidney Disease |
|
|
670 | (4) |
|
|
674 | (1) |
|
|
674 | (1) |
|
|
674 | (5) |
|
92 Vitamin D Receptor Antagonists |
|
|
|
|
|
679 | (1) |
|
|
680 | (3) |
|
|
683 | (1) |
|
|
684 | (1) |
|
|
685 | (1) |
|
TEI-9647 and Its Derivatives |
|
|
686 | (3) |
|
|
689 | (1) |
|
Nonsecosteroidal Vitamin D Receptor Antagonist |
|
|
690 | (1) |
|
Conclusion and Directions for Future Study |
|
|
691 | (1) |
|
|
691 | (4) |
|
93 Eldecalcitol and Osteoporosis |
|
|
|
|
|
|
695 | (1) |
|
Structure--Function Relationship |
|
|
696 | (2) |
|
|
698 | (3) |
|
|
701 | (1) |
|
Clinical Studies in Osteoporotic Patients |
|
|
701 | (4) |
|
|
705 | (1) |
|
|
705 | (6) |
|
|
|
94 Overview of Vitamin D Actions in Cancer |
|
|
|
|
Johannes P.T.M. Van Leeuwen |
|
|
|
|
|
711 | (1) |
|
|
711 | (7) |
|
Vitamin D Effects on Tumor Cells |
|
|
718 | (6) |
|
|
724 | (2) |
|
Resistance and Vitamin D Metabolism |
|
|
726 | (1) |
|
Stimulation of Proliferation |
|
|
727 | (1) |
|
|
728 | (1) |
|
|
728 | (15) |
|
95 Vitamin D Status and Cancer Incidence, Mortality, and Prognosis |
|
|
|
|
|
|
743 | (1) |
|
|
744 | (2) |
|
Cancer Mortality and Survival |
|
|
746 | (7) |
|
|
753 | (9) |
|
96 Effects of Vitamin D Derivatives on Differentiation, Cell Cycle, and Apoptosis in Hematological Malignancies |
|
|
|
|
|
|
|
Differentiation of Myeloid Leukemia Cells by Vitamin D Derivatives |
|
|
762 | (1) |
|
Signaling and Execution of Monocytic Differentiation Induced by Vitamin D Derivatives |
|
|
763 | (5) |
|
Transcription Factors in Vitamin D Derivative-Induced Differentiation |
|
|
768 | (1) |
|
Role of Micro-RNAs in Hematopoiesis, Differentiation, and Cell Cycle Block |
|
|
769 | (1) |
|
Vitamin D Derivatives--Induced Progression of Monocytic to Macrophage Differentiation |
|
|
770 | (1) |
|
Effects of Vitamin D Derivatives on the Cell Cycle and Proliferation of Human Leukemia Cells |
|
|
771 | (7) |
|
Efects of Vitamin D Derivatives on Cell Survival and Cell Death |
|
|
778 | (1) |
|
Effects of Vitamin D Derivatives on Lymphoid Lineage Cells |
|
|
779 | (1) |
|
Clinical Applications of Vitamin D Derivatives' Actions Against Hematopoietic Malignancies |
|
|
780 | (7) |
|
|
787 | (1) |
|
|
787 | (15) |
|
97 Vitamin D Actions in Mammary Gland and Breast Cancer: Genomics, Metabolism, and Stem Cells |
|
|
|
|
|
Introduction to Breast Cancer |
|
|
802 | (1) |
|
Observational and Interventional Studies on Vitamin D and Breast Cancer |
|
|
803 | (2) |
|
Expression and Function of the Vitamin D Pathway in Normal and Neoplastic Breast Cells/Tissues |
|
|
805 | (2) |
|
Impact of Vitamin D Signaling in Animal Models of Breast Cancer |
|
|
807 | (2) |
|
Genomic Profiling of Vitamin D Receptor Agonists in Breast Cancer Model Systems |
|
|
809 | (2) |
|
New Mechanistic Insight Into Vitamin D Actions in Breast Cancer |
|
|
811 | (3) |
|
Overall Conclusions and Remaining Research Questions |
|
|
814 | (1) |
|
|
814 | (7) |
|
98 The Antitumor Effects of Vitamin D in Genitourinary Cancer |
|
|
|
|
|
821 | (1) |
|
|
822 | (6) |
|
|
828 | (1) |
|
|
829 | (1) |
|
|
830 | (1) |
|
|
831 | (5) |
|
|
836 | (2) |
|
99 Vitamin D and Colon Cancer |
|
|
|
|
|
|
Jose Manuel Gonzalez-Sancho |
|
|
|
|
838 | (3) |
|
|
841 | (1) |
|
Expression of Vitamin D Hydroxylases and the Vitamin D Receptor in Colon Cancer |
|
|
842 | (2) |
|
Mechanism of Action of 1,25(OH)2D3 in Colon Cancer |
|
|
844 | (8) |
|
|
852 | (3) |
|
|
855 | (1) |
|
|
855 | (8) |
|
100 Vitamin D and Skin Cancer |
|
|
|
|
|
|
|
863 | (1) |
|
Two Sources of Vitamin D: Diet or Sunlight |
|
|
863 | (2) |
|
Vitamin D and Indoor Tanning |
|
|
865 | (1) |
|
UV Exposure Contributes to the Development of Melanoma and Nonmelanoma Skin Cancer |
|
|
866 | (1) |
|
Vitamin D in Skin Cancer: Role of Vitamin D in Keratinocytes |
|
|
867 | (1) |
|
Role of Vitamin D in Squamous Cell Carcinomas |
|
|
867 | (1) |
|
Role of Vitamin D in Basal Cell Carcinomas |
|
|
868 | (1) |
|
Role of Vitamin D in Melanoma |
|
|
869 | (1) |
|
Photoprotection and Vitamin D Levels |
|
|
870 | (1) |
|
|
870 | (1) |
|
|
870 | (6) |
|
101 Vitamin D and Lung Cancer |
|
|
|
|
|
|
|
876 | (1) |
|
|
876 | (1) |
|
Vitamin D and Chronic Obstructive Pulmonary Disease |
|
|
877 | (1) |
|
Variation in Vitamin D Signaling Pathway Components and Lung Cancer Risk/Outcomes |
|
|
878 | (1) |
|
Vitamin D and the Chemoprevention of Nonsmall Cell Lung Cancer |
|
|
879 | (1) |
|
Vitamin D Actions in Nonsmall Cell Lung Cancer |
|
|
880 | (4) |
|
Vitamin D-Based Combination Therapies for Advanced Nonsmall Cell Lung Cancer: Preclinical Rationale and Clinical Studies |
|
|
884 | (1) |
|
Activity of Calcitriol Analogs in Nonsmall Cell Lung Cancer Models |
|
|
884 | (1) |
|
|
885 | (1) |
|
|
885 | (1) |
|
|
885 | (7) |
|
102 Vitamin D Inflammation and Cancer |
|
|
|
|
|
|
892 | (1) |
|
Vitamin D and the Vitamin D System |
|
|
893 | (1) |
|
|
893 | (3) |
|
Inflammation-Associated Cancer |
|
|
896 | (8) |
|
|
904 | (1) |
|
|
904 | (11) |
|
XI IMMUNITY, INFLAMMATION AND DISEASE |
|
|
|
103 Vitamin D and Tuberculosis |
|
|
|
|
|
|
|
915 | (1) |
|
The Immune Response in Tuberculosis |
|
|
916 | (1) |
|
Influence of Vitamin D on the Immune Response to Mycobacterium tuberculosis |
|
|
916 | (3) |
|
|
919 | (1) |
|
Studies With Mycobacterium tuberculosis Infection as an End Point |
|
|
920 | (1) |
|
Studies With Active Tuberculosis Disease as End Point |
|
|
921 | (6) |
|
Studies of Treatment Outcome |
|
|
927 | (2) |
|
|
929 | (1) |
|
|
929 | (9) |
|
104 Vitamin D and Adaptive Immunology in Health and Disease |
|
|
|
|
|
|
Epidemiological Evidence for a Role of Vitamin D in Immune Disease |
|
|
938 | (1) |
|
Actions of Vitamin D on Proinflammatory T Lymphocyte Responses |
|
|
938 | (1) |
|
Actions of Vitamin D on Regulatory T Lymphocyte Responses |
|
|
939 | (1) |
|
Actions of Vitamin D on B Lymphocytes |
|
|
940 | (1) |
|
Actions of Vitamin D on the Immune Microenvironment and the Function of Antigen-Presenting Cells |
|
|
940 | (1) |
|
Vitamin D and Vaccine Responses |
|
|
941 | (1) |
|
Translational Studies as a Window to Study Effects of Vitamin D on Adaptive Immunology |
|
|
942 | (1) |
|
Disparity Between Association, Translational, and Clinical Studies |
|
|
942 | (2) |
|
Ultraviolet B Versus Oral Vitamin D Supplementation---Effects on the Adaptive Immune System |
|
|
944 | (1) |
|
Vitamin D as a Temporal Regulator of Adaptive Immune Responses |
|
|
944 | (1) |
|
|
944 | (1) |
|
|
945 | (6) |
|
105 Vitamin D and Innate Immunity |
|
|
|
|
|
|
|
951 | (1) |
|
|
951 | (1) |
|
Mechanisms for Pathogen Sensing |
|
|
952 | (2) |
|
Barrier Function and Associated Infectious Diseases |
|
|
954 | (1) |
|
Innate Immune Activity of 1,25-Dihydroxyvitamin D |
|
|
954 | (3) |
|
Vitamin D Pathway and Tuberculosis |
|
|
957 | (2) |
|
Vitamin D Pathway and Leprosy |
|
|
959 | (1) |
|
History of Vitamin D, Sunshine, and Tuberculosis Treatment |
|
|
960 | (1) |
|
|
961 | (1) |
|
|
961 | (8) |
|
106 Vitamin D and Diabetes |
|
|
|
|
|
|
|
969 | (1) |
|
Vitamin D and Genetic Predisposition to Diabetes |
|
|
970 | (1) |
|
Vitamin D, the Beta Cell, and Insulin Resistance in Type 2 Diabetes |
|
|
971 | (3) |
|
Vitamin D as an Immune Modulator in Type 1 Diabetes |
|
|
974 | (6) |
|
Conclusions and Clinical Perspectives |
|
|
980 | (1) |
|
|
981 | (9) |
|
107 Vitamin D and Multiple Sclerosis |
|
|
|
|
|
|
990 | (1) |
|
Genes and Environment in Multiple Sclerosis |
|
|
991 | (1) |
|
Vitamin D and Multiple Sclerosis Risk and Severity |
|
|
992 | (3) |
|
Vitamin D Signaling in the Immune and Nervous Systems |
|
|
995 | (2) |
|
Vitamin D Mechanisms of Immune Regulation |
|
|
997 | (3) |
|
Vitamin D Mechanisms of Neuroprotection |
|
|
1000 | (2) |
|
Rising Multiple Sclerosis Incidence in Women |
|
|
1002 | (1) |
|
Sex-Based Differences in Multiple Sclerosis and the Role of Estrogen |
|
|
1002 | (1) |
|
Vitamin D and Estrogen Synergy for T Cell Self-Tolerance |
|
|
1003 | (2) |
|
Declining Vitamin D Status and Rising Multiple Sclerosis Incidence |
|
|
1005 | (2) |
|
Vitamin D and Multiple Sclerosis Prevention |
|
|
1007 | (2) |
|
Conclusions and Unanswered Questions |
|
|
1009 | (1) |
|
|
1009 | (1) |
|
|
1010 | (15) |
|
108 Vitamin D and Inflammatory Bowel Disease |
|
|
|
|
|
|
1025 | (1) |
|
What Is Inflammatory Bowel Disease? |
|
|
1025 | (1) |
|
Who Gets Inflammatory Bowel Disease? |
|
|
1026 | (2) |
|
The Gut Epithelium, Commensals, and Inflammatory Bowel Disease |
|
|
1028 | (1) |
|
The Immune Response and Inflammatory Bowel Disease |
|
|
1028 | (1) |
|
Vitamin D Regulates T Cell Responsiveness |
|
|
1029 | (1) |
|
Experimental Models of Inflammatory Bowel Disease |
|
|
1030 | (1) |
|
Vitamin D and the Microbiota |
|
|
1031 | (1) |
|
Current Treatments for Inflammatory Bowel Disease |
|
|
1032 | (1) |
|
Vitamin D as a Treatment Option for Inflammatory Bowel Disease |
|
|
1033 | (1) |
|
|
1033 | (1) |
|
|
1033 | (4) |
|
109 Psoriasis and Other Skin Diseases |
|
|
|
|
|
Introduction/Historical Overview |
|
|
1037 | (1) |
|
Pathogenesis of Psoriasis |
|
|
1038 | (1) |
|
The Vitamin D System in Normal and Psoriatic Skin |
|
|
1038 | (2) |
|
Physiological and Pharmacological Actions of Vitamin D Analogs in Normal and Psoriatic Skin |
|
|
1040 | (3) |
|
Clinical Use of 1,25(OH)2D3 and Its Analogs in Psoriasis and Other Skin Diseases |
|
|
1043 | (2) |
|
Vitamin D Analog Therapy in Other Skin Diseases |
|
|
1045 | (1) |
|
Evaluation of New Vitamin D Analogs, With Less Calcemic Activity, Which Can Be Used for the Treatment of Hyperproliferative Skin Disorders |
|
|
1046 | (1) |
|
|
1047 | (1) |
|
|
1047 | (9) |
|
XII THERAPEUTIC APPLICATIONS AND NEW ADVANCES |
|
|
|
110 Sunlight Protection by Vitamin D Compounds |
|
|
|
|
|
|
|
1056 | (1) |
|
DNA Damage by Ultraviolet Radiation |
|
|
1056 | (2) |
|
|
1058 | (2) |
|
Ultraviolet-Induced Immune Suppression |
|
|
1060 | (1) |
|
Synthesis and Metabolism of Vitamin D Compounds in Skin |
|
|
1061 | (1) |
|
The Vitamin D System and Photocarcinogenesis |
|
|
1061 | (2) |
|
Vitamin D Compounds Reduce Several Types of Ultraviolet-Induced DNA Damage |
|
|
1063 | (2) |
|
Vitamin D Compounds and UV-Induced Immune Suppression |
|
|
1065 | (1) |
|
Pathways---Evidence for Involvement of Nonclassical Pathways |
|
|
1066 | (2) |
|
|
1068 | (1) |
|
|
1069 | (8) |
|
111 Vitamin D, Cardiovascular Disease, and Hypertension |
|
|
|
|
|
1077 | (1) |
|
|
1078 | (1) |
|
|
1078 | (2) |
|
|
1080 | (2) |
|
Mendelian Randomization Studies |
|
|
1082 | (1) |
|
Randomized Controlled Trials |
|
|
1083 | (2) |
|
|
1085 | (1) |
|
|
1086 | (1) |
|
|
1087 | (9) |
|
112 Vitamin D, Acute Respiratory Infection, and Asthma/Chronic Obstructive Pulmonary Disease |
|
|
|
|
|
1096 | (1) |
|
Common Respiratory Disorders |
|
|
1096 | (3) |
|
Vitamin D and Lung Development |
|
|
1099 | (1) |
|
Vitamin D and Acute Respiratory Infection |
|
|
1100 | (3) |
|
|
1103 | (4) |
|
Vitamin D and Chronic Obstructive Pulmonary Disease |
|
|
1107 | (2) |
|
|
1109 | (3) |
|
|
1112 | (2) |
|
|
1114 | (1) |
|
|
1114 | (1) |
|
|
1114 | (7) |
|
113 Vitamin D and Muscle Performance in Athletes |
|
|
|
|
|
|
1121 | (1) |
|
Historical Links Between Vitamin D and Athletic Performance |
|
|
1121 | (1) |
|
Basic Research Influencing Interest in Vitamin D in Athletic Performance |
|
|
1122 | (2) |
|
Clinical Research Influencing Interest in Vitamin D in Athletic Performance |
|
|
1124 | (1) |
|
Recent Clinical Research in Athletes |
|
|
1124 | (3) |
|
|
1127 | (1) |
|
|
1127 | (4) |
|
114 Vitamin D: Presence and Function in the Eye |
|
|
|
|
|
|
|
1131 | (1) |
|
|
1132 | (1) |
|
|
1133 | (1) |
|
|
1133 | (2) |
|
|
1135 | (1) |
|
|
1136 | (1) |
|
|
1136 | (2) |
|
Age-Related Macular Degeneration |
|
|
1138 | (3) |
|
|
1141 | (1) |
|
|
1142 | (1) |
|
|
1143 | (4) |
|
115 Adult Vitamin D Deficiency and Adverse Brain Outcomes |
|
|
|
|
|
|
|
1147 | (1) |
|
|
1147 | (4) |
|
|
1151 | (3) |
|
|
1154 | (1) |
|
|
1155 | (1) |
|
|
1155 | (4) |
|
116 Vitamin D in Pregnancy and Lactation: Moving Into the Future |
|
|
|
|
|
|
1159 | (1) |
|
Vitamin D Nomenclature and Metabolism |
|
|
1160 | (1) |
|
Vitamin D Metabolism During Pregnancy When Compared With the Nonpregnant State Including Lactation |
|
|
1160 | (2) |
|
Obstetrical "Paranoia" Regarding Vitamin D Administration During Pregnancy |
|
|
1162 | (1) |
|
Observational Studies Suggesting the Function of Vitamin D Extended Beyond Calcium Homeostasis During Pregnancy |
|
|
1162 | (1) |
|
Randomized Controlled Trials Investigating Vitamin D Supplementation During Pregnancy |
|
|
1163 | (2) |
|
Supplementing Vitamin D During Pregnancy to Prevent Childhood Asthma |
|
|
1165 | (3) |
|
Neurodevelopment and Autoimmune Consequences |
|
|
1168 | (1) |
|
Current Recommendation for Vitamin D Supplementation During Pregnancy |
|
|
1168 | (1) |
|
Vitamin D Requirements of the Mother/Infant Dyad During Lactation |
|
|
1169 | (1) |
|
Altering the Vitamin D Content of Human Milk |
|
|
1169 | (1) |
|
Interventional and RCTs to Determine if Maternal Vitamin D Supplementation Can Supply Adequate Vitamin D to the Nursing Infant |
|
|
1169 | (2) |
|
Current Recommendation for Maternal Vitamin D Supplementation During Lactation |
|
|
1171 | (1) |
|
|
1171 | (1) |
|
|
1172 | (1) |
|
|
1172 | |
|
117 Vitamin D and Critically Intensive Care Unit Patients |
|
|
111 | |
|
|
|
1177 | |
|
Prevalence of Vitamin D Deficiency in the Critically |
|
|
111 | |
|
|
1178 | |
|
Vitamin D Deficiency Risk Factors in the Critically |
|
|
111 | |
|
|
1178 | (1) |
|
Vitamin D Mechanism in Critical Illness |
|
|
1179 | (1) |
|
|
1180 | (1) |
|
|
1181 | (1) |
|
|
1181 | (1) |
|
|
1181 | (1) |
|
Metabolomics, Transcriptomics, and Epigenetics of Vitamin D |
|
|
1182 | (1) |
|
|
1183 | (1) |
|
|
1183 | (1) |
|
Vitamin D and Critical Illness Outcomes |
|
|
1183 | (1) |
|
|
1183 | (1) |
|
|
1183 | (1) |
|
|
1184 | (1) |
|
|
1184 | (2) |
|
|
1186 | (1) |
|
Is Vitamin D Supplementation Safe? |
|
|
1186 | (1) |
Conclusions |
|
1187 | (1) |
References |
|
1187 | (8) |
Index for Volume 2 |
|
1195 | |